MFC stock gets a fresh Barclays target lift as analysts stay bullish

Published on 10/07/2026 at 17:00 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

MFC stock was last at C$61.17 on October 6, while 12 analysts set an average target of C$66.00. Q2 core EPS rose 16 percent year over year.

MFC, CA56501R1064, Illustration mit AI erstellt.

MFC stock was last at C$61.17 on the Toronto Stock Exchange on October 6, 2026, down 0.20 percent from the previous session. TheFly reported on October 7, 2026, that Barclays raised its Manulife price target by C$2, giving the stock a fresh analyst catalyst after the second-quarter report already covered by the company news cycle.

Barclays lifts its target

The Barclays action adds to a positive analyst backdrop, but the exact new target was not stated in the published item. The move matters because Manulife shares were below the broader consensus target of C$66.00 on the latest Toronto quote.

Q2 growth came from Asia

Manulife's second-quarter 2026 operating figures showed APE sales up 21 percent year over year and core EPS up 16 percent. According to Benzinga on October 5, 2026, Asia core earnings increased 21 percent, while Global Wealth and Asset Management core earnings rose 9 percent.

The same Q2 2026 call showed core return on equity of 16.3 percent, an increase of 130 basis points from the prior-year quarter. Manulife also said its LICAT ratio was 136 percent, leaving capital strength and the pace of shareholder returns as important parts of the investment case.

Consensus stays above the quote

MarketBeat lists a Buy consensus from 12 analysts, including 10 Buy ratings, one Hold and one Strong Buy. The average 12-month target is C$66.00, with a C$59.00 low and C$70.00 high, placing the average target 7.90 percent above the quoted C$61.17.

MFC stays below the consensus

MFC was last at C$61.17 on the Toronto Stock Exchange on October 6, 2026, with the -0.20 percent session move keeping the share price below the analyst average. The combination of double-digit Q2 growth and a fresh Barclays target revision leaves earnings execution and claims trends as the next key tests.